Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
Status:
Withdrawn
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the proportion of subjects with HIV-1 RNA < 50 c/mL
at Week 48 in patients who failed their first line therapy containing a non-nucleoside
reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor